Task order no. 2 - "van leyen mcsp-EC"
Ended Awarded Last action
- Contract number
- 75N95018F00002
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,403,139
Award facts
- Opportunity
-
- NIHNINDS1701 Solicitation number
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Mar 19, 2018
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Jun 30, 2017
- Contract value 100% obligated
- $3,403,139.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$39,926 | |
| Funding Only Action | -$2,228 | |
| Funding Only Action | -$0 | |
| Exercise an Option | $1,552,302 | |
| Exercise an Option | $1,391,268 | |
| Original award | $501,724 |
About this award
This is a delivery order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency within the National Institutes of Health (NIH), to Curia Global Inc. (doing business as Amri), a for-profit organization and manufacturer of goods. The $3,403,139.10 cost-plus-fixed-fee contract is for the "VAN LEYEN MCSP-EC" task order, which is part of the Medicinal Chemistry Support Program for Therapeutic Development, a larger IDIQ contract vehicle. The work involves a range of pharmaceutical research and development services, including medicinal chemistry, chemical development, analytical testing, formulation development, and current Good Manufacturing Practices (cGMP) manufacturing, to support NINDS' therapeutic development initiatives in areas such as neurology, infectious diseases, and substance abuse. No set-aside designation was used for this award.
Quick answers
Who was awarded contract 75N95018F00002?
75N95018F00002 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on May 4, 2018.
How much is contract 75N95018F00002 worth?
The government has obligated $3,403,139 on 75N95018F00002.
Which agency awarded contract 75N95018F00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95018F00002, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95018F00002 an order under another contract?
Yes. 75N95018F00002 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95018F00002 competed?
The extent of competition for 75N95018F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award